Amy Y. Wang

Amy Y. Wang

Auto-generated profile, based on publicly available information

Amy Y. Wang

Informatics Institute, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
YCYu Chen
Yu Chen
AWAmy Y. Wang
Amy Y. Wang
CBCourtney A. Barkley
Courtney A. Barkley
YZYixin Zhang
Yixin Zhang
XZXinyang Zhao
Xinyang Zhao
ZCZechen Chong
Zechen Chong
Long-read sequencing has demonstrated great potential for characterizing all types of structural variations (SVs). However, existing algorithms have insufficient sensitivity and precision. To address these limitations, we present DeBreak, a computational method for comprehensive and accurate SV discovery. Based on alignment results, DeBreak employs a density-based approach for clustering SV candidates together with a local de novo assembly approach for reconstructing long insertions. A partial order alignment algorithm ensures precise SV breakpoints with single base-pair resolution, and a k-means clustering method can report multi-allele SV events. DeBreak outperforms existing tools on both simulated and real long-read sequencing data from both PacBio and Nanopore platforms. An important application of DeBreak is analyzing cancer genomes for potentially tumor-driving SVs. DeBreak can also be used for supplementing whole-genome assembly-based SV discovery.

1 April 2021 in JAMIA Open
Verified
Journal Article
Open access
PDF file
SVShyam Visweswaran
Shyam Visweswaran
MSMalarkodi J Samayamuthu
Malarkodi J Samayamuthu
MMMichele Morris
Michele Morris
GWGriffin M. Weber
Griffin M. Weber
DMDouglas MacFadden
Douglas MacFadden
SRSteven E Reis
Steven E Reis
Clinical data networks that leverage large volumes of data in electronic health records (EHRs) are significant resources for research on coronavirus disease 2019 (COVID-19). Data harmonization is a key challenge in seamless use of multisite EHRs for COVID-19 research. We developed a COVID-19 application ontology in the national Accrual to Clinical Trials (ACT) network that enables harmonization of data elements that are critical to COVID-19 research. The ontology contains over 50 000 concepts in the domains of diagnosis, procedures, medications, and laboratory tests. In particular, it has computational phenotypes to characterize the course of illness and outcomes, derived terms, and harmonized value sets for severe acute respiratory syndrome coronavirus 2 laboratory tests. The ontology was deployed and validated on the ACT COVID-19 network that consists of 9 academic health centers with data on 14.5M patients. This ontology, which is freely available to the entire research community on GitHub at https://github.com/shyamvis/ACT-COVID-Ontology, will be useful for harmonizing EHRs for COVID-19 research beyond the ACT network.

21 January 2022 in Research Square
Verified
Preprint
Open access
PDF file
YCYu Chen
Yu Chen
AWAmy Wang
Amy Wang
CBCourtney Barkley
Courtney Barkley
XZXinyang Zhao
Xinyang Zhao
MGMin Gao
Min Gao
ZCZechen Chong
Zechen Chong
Long-read sequencing has demonstrated great potential for characterizing all types of structural variations (SVs). However, existing algorithms have insufficient sensitivity and precision. To address these limitations, we present DeBreak, a novel method for comprehensive and accurate SV discovery. Based on alignment results, DeBreak employs a density-based approach for clustering SV candidates together with a local de novo assembly approach for reconstructing long insertions. A partial order alignment algorithm ensures precise SV breakpoints with single base-pair resolution, and a k-means clustering method can report multi-allelic SV events. DeBreak outperforms existing tools on both simulated and real long-read sequencing data from both PacBio and Nanopore platforms. An important application of DeBreak is analyzing cancer genomes for potentially tumor-driving SVs. DeBreak also demonstrates excellent performance in supplementing whole-genome assembly methods.